Department of Pediatrics, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China (Gu J-W, Email: GJW888GJW@ 163. com).
Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(9):944-950. doi: 10.7499/j.issn.1008-8830.2103070.
To systematically assess the efficacy and safety of eltrombopag in the treatment of children with immune thrombocytopenia (ITP).
PubMed, Embase, Cochrane Library, Weipu Data, CNKI, and Wanfang Data were searched for studies on eltrombopag used for the treatment of children with ITP. RevMan 5.3 and R version 3.6 were used to perform a Meta analysis of included studies.
A total of 11 studies were included, with 2 randomized controlled trials and 9 cohort studies. The Meta analysis of the 9 cohort studies showed that eltrombopag had a response rate of about 70% (95%: 65%-76%) in the treatment of children with ITP, with no serious adverse events. The Meta analysis of the randomized controlled trials showed that the eltrombopag group had a higher response rate than the placebo group (=2.64, 95%: 1.58-4.44, <0.05), while there was no significant difference in the incidence rates of adverse events and serious adverse events between the two groups (>0.05).
Eltrombopag has good efficacy and safety as a second-line treatment regimen for children with ITP.
系统评估艾曲波帕治疗儿童免疫性血小板减少症（ITP）的疗效和安全性。
检索 PubMed、Embase、Cochrane 图书馆、维普数据库、中国知网和万方数据，查找艾曲波帕治疗儿童 ITP 的研究。使用 RevMan 5.3 和 R 版本 3.6 对纳入研究进行 Meta 分析。
共纳入 11 项研究，其中 2 项为随机对照试验，9 项为队列研究。9 项队列研究的 Meta 分析结果显示，艾曲波帕治疗儿童 ITP 的有效率约为 70%（95%置信区间：65%-76%），无严重不良事件。随机对照试验的 Meta 分析结果显示，艾曲波帕组的有效率高于安慰剂组（=2.64，95%置信区间：1.58-4.44，<0.05），但两组不良反应和严重不良反应发生率无显著差异（>0.05）。
艾曲波帕作为儿童 ITP 的二线治疗方案，疗效好，安全性高。
